Myosin Therapeutics Inc.
Publicly observedJupiter, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Jupiter | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Myosin Therapeutics Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MLH1HUK133H3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomas
USD 249,417.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2025Publicly observed
NIH SBIR/STTR award: Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2
USD 1,496,586.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2023Publicly observed
NIH SBIR/STTR award: Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas
USD 2,241,448.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2023Publicly observed
NIH SBIR/STTR award: Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas
USD 2,245,802.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2023Publicly observed
NIH SBIR/STTR award: MT-125 for the Therapeutic Treatment of Glioblastoma
USD 911,407.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.